ERBB2 and gastric cancer: In metastatic/unresectable HER2-negative GC patients, those with a higher relative abundance of Lactobacillus exhibited better responses to immunotherapy and longer PFS, suggesting that Lactobacillus may serve as a novel adjuvant to enhance the efficacy of immunotherapy in GC [107].